Selectivity: Ipamorelin does not significantly increase cortisol or ACTH at therapeutic doses [2]
While observational findings of that magnitude should always be interpreted cautiously, it raises an important hypothesis that GLP-1 therapies may be addressing several interconnected disease pathways simultaneously obesity, inflammation, cardiometabolic dysfunction, and possibly thrombosis, he continued
doi: 10.1038/s41572-021-00321-x 153 ZanframundoGTripoliACometiLMarcucciEFuriniFCavagnaLet al
2006;3(4):628 to 638
The Ohio Department of Administrative Services (DAS) announced that starting July 1st, GLP-1 medications would no longer be covered by the states benefits plan for weight loss
Jamie Alan, PhD, an associate professor of pharmacology and toxicology at Michigan State University, says people with Type 2 diabetes can benefit from metformin, DPP-4 inhibitors, and SGLT-2 inhibitors (The study did find that people with variant p.S539W responded like everyone else to these medications.) Dr